Lymphopenia and eosinophilia in dimethyl fumarate treated patients

被引：0
|
作者：
Vinagre Aragon, A. [1 ]
Garcia Malo, C. [1 ]
Novo Ponte, S. [1 ]
Mena Romo, L. [1 ]
Moreno Torres, I. [1 ]
Blasco Quilez, M. R. [1 ]
Garcia Merino, A. [1 ]
机构：
[1] Hosp Puerta de Hierro, Neurol, Madrid, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1236
引用
收藏
页码：651 / 651
页数：1
相关论文
共 50 条
  • [31] Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia
    Diebold, Martin
    Galli, Edoardo
    Kopf, Andreas
    Sanderson, Nicholas
    Callegari, Ilaria
    Ingelfinger, Florian
    Nunez, Nicolas Gonzalo
    Benkert, Pascal
    Kappos, Ludwig
    Kuhle, Jens
    Becher, Burkhard
    Claassen, Manfred
    Derfuss, Tobias
    ANNALS OF NEUROLOGY, 2022, 91 (05) : 676 - 681
  • [32] Lymphocyte decline and reconstitution after discontinuation in patients with severe, prolonged lymphopenia treated with delayed-release dimethyl fumarate
    Fox, R. J.
    Chan, A.
    Gold, R.
    Phillips, J. T.
    Yang, L.
    Liu, S.
    Chalkias, S.
    Mehta, D.
    Taylor, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 371 - 371
  • [33] Lymphopenia in patients treated with dimethyl fumarate. Risk factors and clinical significance. Experience in daily clinical practice
    Valero Lopez, G.
    Alba Isasi, M. T.
    Carreon Guarnizo, E.
    Hernandez Clares, R.
    Canovas Iniesta, M.
    Morales De La Prida, M.
    Iniesta Martinez, F.
    Morales Ortiz, A.
    Meca-Lallana, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 289 - 290
  • [34] Prevalence and predictors of lymphopenia in multiple sclerosis (MS) patients treated with fingolimod (FG) or delayed - release dimethyl fumarate (DMF)
    Baharnoori, M.
    Chua, A.
    Diaz-Cruz, C.
    Healy, B. C.
    Stankiewicz, J.
    Weiner, H. L.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 354 - 355
  • [35] No Significant Genetic or Transcriptomic Predictors of Severe and Prolonged Lymphopenia in MS Cases Treated with Dimethyl Fumarate
    Bronson, Paola G.
    Sangurdekar, Dipen
    Penny, Michelle
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 61 - 61
  • [36] Factors associated with dimethyl fumarate-induced lymphopenia
    Sainz de la Maza, Susana
    Medina, Silvia
    Villarrubia, Noelia
    Costa-Frossard, Lucienne
    Monreal, Enric
    Tejeda-Velarde, Amalia
    Rodriguez-Martin, Eulalia
    Roldan, Ernesto
    Alvarez-Cermeno, Jose C.
    Villar, Luisa M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 398 : 4 - 8
  • [37] Persistent lymphopenia after dimethyl fumarate and fingolimod treatment
    Hernandez, I.
    Mulero, P.
    Neri, M. J.
    Redondo, N.
    Abad, E.
    Tellez, N.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 644 - 645
  • [38] No Significant Genetic or Transcriptomic Predictors of Severe and Prolonged Lymphopenia in MS Cases Treated with Dimethyl Fumarate
    Bronson, Paola
    Sangurdekar, Dipen
    Penny, Michelle
    NEUROLOGY, 2018, 90
  • [39] More on PML in Patients Treated with Dimethyl Fumarate REPLY
    Murk, Jean-Luc
    Nieuwkamp, Dennis J.
    van Oosten, Bob W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03): : 296 - 296
  • [40] Lymphopenia in patients on dimethyl fumarate (DMF): data from the providence multiple sclerosis center
    Smoot, K. E.
    Chen, C.
    Baraban, E.
    Grote, L.
    Kresa-Reahl, K.
    Cohan, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 292 - 293
12345